Literature DB >> 9725199

Dendritic cells require maturation via CD40 to generate protective antitumor immunity.

M F Mackey1, J R Gunn, C Maliszewsky, H Kikutani, R J Noelle, R J Barth.   

Abstract

A critical role for CD40/CD154 interactions in the generation of protective cell-mediated tumor immunity has been demonstrated previously. Herein, we show that the failure to generate systemic tumor immunity in the absence of CD40/CD154 interactions correlates with an inhibition of Th1-type cytokine production following tumor vaccination. Furthermore, protective antitumor responses can be restored in CD40-deficient mice by the coadministration of CD40+/+ but not CD40-/- dendritic cells (DCs) with tumor Ag, suggesting that CD40 is critical for the maturation and function of DCs in vivo. Finally, we demonstrate that an IL-12-transduced but not a mock-transduced tumor vaccine induces systemic tumor immunity in anti-CD154-treated and CD154-deficient mice. These data suggest that impaired antitumor responses in the absence of CD40/CD154 interactions are the result of a lesion in APC function, namely IL-12 production, and that CD40 plays a critical role in the maturation of DCs in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725199

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.

Authors:  J D Ahlers; I M Belyakov; E K Thomas; J A Berzofsky
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

Review 3.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

4.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Authors:  Stefani Spranger; Ayelet Sivan; Leticia Corrales; Thomas F Gajewski
Journal:  Adv Immunol       Date:  2016-01-22       Impact factor: 3.543

5.  Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.

Authors:  Sadia Zafar; Suvi Parviainen; Mikko Siurala; Otto Hemminki; Riikka Havunen; Siri Tähtinen; Simona Bramante; Lotta Vassilev; Hongjie Wang; Andre Lieber; Silvio Hemmi; Tanja de Gruijl; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

6.  CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection.

Authors:  J X Gao; J Madrenas; W Zeng; M J Cameron; Z Zhang; J J Wang; R Zhong; D Grant
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

7.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

8.  CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.

Authors:  Aristides Moschonas; Maria Kouraki; Pauline G Knox; Efstathia Thymiakou; Dimitris Kardassis; Aristides G Eliopoulos
Journal:  Mol Cell Biol       Date:  2008-08-11       Impact factor: 4.272

9.  A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

Authors:  Erin E Thacker; Masaharu Nakayama; Bruce F Smith; R Curtis Bird; Zhanat Muminova; Theresa V Strong; Laura Timares; Nikolay Korokhov; Ann Marie O'Neill; Tanja D de Gruijl; Joel N Glasgow; Kenzaburo Tani; David T Curiel
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

10.  Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Authors:  Feorillo Galivo; Rosa Maria Diaz; Uma Thanarajasingam; Dragan Jevremovic; Phonphimon Wongthida; Jill Thompson; Timothy Kottke; Glen N Barber; Alan Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.